Y-mabs therapeutics.

May 23, 2023 · NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária ... Clearance of CD38-SADA IND marks the second clinical development program utilizing the Company’s novel SADA technology platform. NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for ...Y-mAbs Therapeutics, Inc. today announced that the first patient has been dosed with both the protein dose and the 177Lu-DOTA imaging dose in its Phase 1 clinical trial, evaluating the Company’s pre-targeted radioimmunotherapy Self-Assembly and Disassembly-Bispecific (“SADA”) technology platform for the treatment of certain GD2 …NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter ...

Get Y-mAbs Therapeutics Inc. (YMAB) share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial ...08 Apr 2022 Y-mAbs Therapeutics terminates a phase I/II trial in Small cell lung cancer (Metastatic disease, Second-line therapy or greater, Recurrent) in USA due to business priorities (SC) (NCT04750239) 20 Oct 2021 Y-mAbs Therapeutics terminates phase I/II trial in Osteosarcoma (In adolescents, In adults, In children, In the elderly, …

Thomas Gad founded Y-mAbs Therapeutics in April 2015 and has been a member of the Board of Directors since the Company’s inception. Mr. Gad serves as Founder, Vice Chairman of the Board of Directors, and Chief Business Officer. Inspired by his daughter’s transformational and challenging journey through years of high-risk neuroblastoma …Jul 12, 2022 · NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced initiation of its first clinical trial with a SADA construct.

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the European Medicines …Y-mAbs Therapeutics Inc. (Y-mAbs) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center.Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein ...NEW YORK, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced clinical data on the Company’s product candidate OMBLASTYS® (131 I-omburtamab) for the ...Y-Mabs Therapeutics (YMAB) has a Smart Score of 9 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, ...

DANYELZA (naxitamab-gqgk) 40mg/10mL Injection Learn more at danyelza.com Please click for full Prescribing Information and Patient Information for DANYELZA including BOXED WARNING on serious infusion-related reactions and neurotoxicity. MORE INFO Y-mAbs ConnectTM provides answers to questions related to access, insurance, financial support programs and other resource programs for qualifying ...

Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 106.82% and 50.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for ...

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic cancer products. In addition to conventional antibodies, the Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform.Nov 17, 2023 · Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) issued its earnings results on Monday, May, 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.16. The business earned $20.30 million during the quarter, compared to analysts' expectations of $15.55 million. 131I-omburtamab, a potential treatment for patients with neuroblastoma who have developed central nervous system or leptomeningeal metastases, has been issued a complete response letter from the FDA, according to a press release from Y-mAbs Therapeutics. 1 After reviewing omburtamab’s biologics license application, the FDA …NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that clinical experience for …Thomas Gad founded Y-mAbs Therapeutics in April 2015 and has been a member of the Board of Directors since the Company’s inception. Mr. Gad serves as Founder, Vice Chairman of the Board of Directors, and Chief Business Officer. Inspired by his daughter’s transformational and challenging journey through years of high-risk neuroblastoma treatment and her experience …

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer ...NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the first patient has been dosed with both the protein dose and the 177Lu-DOTA ...Y-mAbs is committed to making a difference in pediatric oncology outcomes. Pediatric cancer has long been a challenge for the medical profession. With years of growing knowledge and insights, advancements are being made through research that may change protocols. Y-mAbs is working to develop targeted approaches to treating rare and challenging ...Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein ...Y-mAbs Platform Overview Y-mAbs is focused on creating innovations in three key areas: immunotherapies, radioimmunotherapies, and companion diagnostics. Although each platform serves a different purpose, there are synergizing aspects between them: Immunotherapies help the body’s own immune system fight cancer by targeting specific pathways in tumor cells Radioimmunotherapies build off of the ...

15 jan 2021 ... Acquired Entities. Y-mAbs Therapeutics, Inc. More Resources.Michael Rossi is President, Chief Executive Officer, and a member of the Board of Directors of Y-mAbs Therapeutics. Mr. Rossi has more than 30 years of radiopharmaceutical, drug development, commercialization, and people leadership experience on a global scale, most recently as President, Medical Group at Mirion Technologies.

Founders Thomas Gad. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Y-mAbs Therapeutics, Inc. Stock Symbol NASDAQ:YMAB. Company Type For Profit. Contact Email [email protected]. Phone Number 1 212 847 9841. YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer ... Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein ...WHAT IS DANYELZA? DANYELZA is a prescription medicine used in combination with a medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children 1-year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that:Burned by FDA rejection, Y-mAbs drops 3rd of staff, cancer vaccine ambitions. By James Waldron Jan 5, 2023 8:40am. Y-mAbs Therapeutics layoffs cancer vaccine FDA advisory committee. In the wake of ...Y-mAbs is a biopharmaceutical company that develops antibody-based products for the treatment of cancer, with a focus on rare and challenging pediatric …Y-mAbs is developing several strategies to guide the immune system for precise tumor killing. 1. Monoclonal antibodies (mAbs) Monoclonal antibodies (mAbs) are engineered proteins designed to target tumor …In 2015, the FDA and the EMA, approved Unituxin (dinutuximab), a monoclonal GD2-targeting antibody developed by United Therapeutics Corporation, or United Therapeutics, and administered in combination with GM-CSF, interleukin-2, or IL-2, and isotretinoin, also known as 13-cis-retinoic acid, for the treatment of pediatric patients with high-risk ...Y-mAbs Platform Overview Y-mAbs is focused on creating innovations in three key areas: immunotherapies, radioimmunotherapies, and companion diagnostics. Although each platform serves a different purpose, there are synergizing aspects between them: Immunotherapies help the body’s own immune system fight cancer by targeting specific …In 2015, the FDA and the EMA, approved Unituxin (dinutuximab), a monoclonal GD2-targeting antibody developed by United Therapeutics Corporation, or United Therapeutics, and administered in combination with GM-CSF, interleukin-2, or IL-2, and isotretinoin, also known as 13-cis-retinoic acid, for the treatment of pediatric patients with high-risk ...NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher ...

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k ...

Cancer immunotherapy works by helping the body’s own immune system to destroy cancer cells. Y-mAbs is developing several strategies to guide the immune system for precise tumor killing. 1. Monoclonal antibodies (mAbs) Monoclonal antibodies (mAbs) are engineered proteins designed to target tumor antigens and bind tumor cells. Y-mAbs is ...

Y Mabs Therapeutics · Market Cap · P/E Ratio (ttm) · Forward P/E · Diluted EPS (ttm) · Dividends Per Share · Dividend Yield · Ex-Dividend Date.Y-mAbs is committed to developing innovative immunotherapies to overcome cancer Y-mAbs isn’t like every other biopharmaceutical company. It was founded by Thomas Gad, President, Head of Business Development and Strategy, and, more importantly, the father of Daniella, a high-risk neuroblastoma survivor. ... Y-mAbs Therapeutics, Inc provides ...Y-Mabs Therapeutics (YMAB) has a Smart Score of 9 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, ...If you purchased or acquired Y-mAbs common stock, and/or would like to discuss your legal rights and options please visit Y-mAbs Therapeutics, Inc. Shareholder Class Action Lawsuit or contact ...We would like to show you a description here but the site won’t allow us.Feb 16, 2023 · For the last reported quarter, it was expected that Y-mAbs Therapeutics, Inc. Would post a loss of $0.75 per share when it actually produced a loss of $0.63, delivering a surprise of +16%. NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug …Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. We have...Oct 19, 2023 · Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein ...

Y-mAbs Therapeutics A/S. Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. We have a broad and advanced product pipeline, including pivotal-stage product candidates against a range of targets.Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. We have ... NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced a strategic restructuring plan designed ...Instagram:https://instagram. sgml stock pricetradeezoper stockbest website for penny stock news When is Y-mAbs Therapeutics's earnings date? Y-mAbs Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings … agnc buy or sellphiladelphia gold and silver index NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it recently completed a Pre …In 2015, the FDA and the EMA, approved Unituxin (dinutuximab), a monoclonal GD2-targeting antibody developed by United Therapeutics Corporation, or United Therapeutics, and administered in combination with GM-CSF, interleukin-2, or IL-2, and isotretinoin, also known as 13-cis-retinoic acid, for the treatment of pediatric patients with high-risk ... qdsix Y-mAbs Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based ...Y-mAbs Therapeutics, Inc. YMAB shares soared 13.8% in the last trading session to close at $5.70. The move was backed by solid volume with far more shares changing hands than in a normal session.